MGMorten Grunnet

Morten Grunnet

*This is an algorithmically generated author record based on publicly available information.

Morten Grunnet has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Søren-Peter Olesen

    Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark

    6 shared publications
  • Rie Schultz Hansen

    From the *Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; and †NeuroSearch A/S, Ballerup, Denmark

    4 shared publications
  • Bo Hjorth Bentzen

    Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark

    3 shared publications
  • Thomas Goldin Diness

    From the *Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; and †NeuroSearch A/S, Ballerup, Denmark

    2 shared publications
  • Thomas Jespersen

    University of Copenhagen

    2 shared publications
  • AP Larsen

    The Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen N, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Central and Peripheral GABAAReceptor Regulation of the Heart Rate Depends on the Conscious State of the Animal

    by Bo Hjorth Bentzen, Morten Grunnet

    Intuitively one might expect that activation of GABAergic inhibitory neurons results in bradycardia. In conscious animals the opposite effect is however observed. GABAergic neurons in nucleus ambiguus hold the ability to control the activity of the parasympathetic vagus nerve that innervates the heart. Upon GABA activation the vagus nerve will be inhibited leaving less parasympathetic impact on the heart. The picture is however blurred in the presence of anaesthesia where both the concentration and type of anaesthetics can result in different effects on the cardiovascular system. This paper reviews cardiovascular outcomes of GABA activation and includes own experiments on anaesthetized animals and isolated hearts. In conclusion, the impact of changes in GABAergic input is very difficult to predict in these settings, emphasizing the need for experiments performed in conscious animals when aiming at determining the cardiovascular effects of compounds acting on GABAergic neurons.


  • Molecular Determinants of Human ether-à-go-go-Related Gene 1 (hERG1) K+ Channel Activation by NS1643

    by Morten Grunnet, Jennifer Abbruzzese, Frank B. Sachse, Michael C. Sanguinetti

    Human ether-à-go-go-related gene 1 (hERG1) channels conduct the rapid delayed rectifier K+ current, IKr, an important determinant of action potential repolarization in mammals, including humans. Reduced IKr function caused by mutations in KCNH2 or drug block of hERG1 channels prolongs the QT interval of the electrocardiogram and increases the risk of ventricular fibrillation and sudden cardiac death. Several activators of hERG1 channels have been discovered in recent years. These compounds shorten the duration of cardiac action potentials and have been proposed as a new therapeutic approach for the treatment of acquired or congenital long QT syndrome. We defined previously the mechanism of action of 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643), a compound that increases hERG1 currents by shifting the voltage-dependence of inactivation to more positive potentials. Here, we use scanning mutagenesis of hERG1 and functional characterization of 56 mutant channels heterologously expressed in Xenopus laevis oocytes to define the molecular determinants of the binding site for NS1643. Most point mutations did not alter response to the drug; however, 10 mutant channels had reduced sensitivity, and F619A and I567A exhibited enhanced activation by the drug. Some of these residues form a cluster and, together with molecular modeling, suggest that NS1643 binds to a pocket near the extracellular ends of the S5/S6 segments of two adjacent hERG1 channel subunits. This putative binding site differs from the sites described previously for two other hERG1 activators, (3R,4R)-4-[3-(6-methoxy-quinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluoro-phenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid (RPR260243) and 2-(4-[2-(3,4-dichloro-phenyl)-ethyl]-phenylamino)-benzoic acid (PD-118057).


  • Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels

    by AP Larsen, Bh Bentzen, M Grunnet

    BACKGROUND AND PURPOSE Kv11.1 channels are involved in regulating cellular excitability in various tissues including brain, heart and smooth muscle. In these tissues, at least two isoforms, Kv11.1a and Kv11.1b, with different kinetics, are expressed. Kv11.1 activators are potential therapeutic agents, but their effects have only been tested on the Kv11.1a isoform. In this study, the effects of two different Kv11.1 activators, NS1643 and RPR260243, were characterized on Kv11.1a and Kv11.1b channels.EXPERIMENTAL APPROACH Kv11.1a and Kv11.1b channels were expressed in Xenopus laevis oocytes, and currents were measured using two‐electrode voltage clamp. I/V curves and channel kinetics were measured before and after application of 30 µM NS1643 or 10 µM RPR260243.KEY RESULTS NS1643 increased steady‐state currents through Kv11.1b several fold more than through Kv11.1a channels, without affecting EC50 values. NS1643 increased activation rates and decreased rates of inactivation, recovery from inactivation and deactivation for both channels. Except for activation, where effect of NS1643 was comparable, relative changes were greater for Kv11.1b than for Kv11.1a. RPR260243 increased steady‐state currents only through Kv11.1a channels, but slowed the process of deactivation for both channels primarily by decreasing time constant of slow deactivation. This effect was greater on Kv11.1b than on Kv11.1a. Effects of both compounds on heteromeric Kv11.1a/Kv11.1b channels were similar to those on Kv11.1a.CONCLUSIONS AND IMPLICATIONS Both NS1643 and RPR260243 displayed differential effects on Kv11.1a and Kv11.1b channels, the effects being relatively more pronounced on Kv11.1b channels. This affirms the importance of testing the effect of Kv11.1 activators on different channel isoforms.


  • Repolarization of the cardiac action potential. Does an increase in repolarization capacity constitute a new anti‐arrhythmic principle?

    by M. Grunnet

    The cardiac action potential can be divided into five distinct phases designated phases 0–4. The exact shape of the action potential comes about primarily as an orchestrated function of ion channels. The present review will give an overview of ion channels involved in generating the cardiac action potential with special emphasis on potassium channels involved in phase 3 repolarization. In humans, these channels are primarily Kv11.1 (hERG1), Kv7.1 (KCNQ1) and Kir2.1 (KCNJ2) being the responsible α‐subunits for conductingIKr,IKsandIK1. An account will be given about molecular components, biophysical properties, regulation, interaction with other proteins and involvement in diseases. Both loss and gain of function of these currents are associated with different arrhythmogenic diseases. The second part of this review will therefore elucidate arrhythmias and subsequently focus on newly developed chemical entities having the ability to increase the activity ofIKr,IKsandIK1. An evaluation will be given addressing the possibility that this novel class of compounds have the ability to constitute a new anti‐arrhythmic principle. Experimental evidence fromin vitro,ex vivoandin vivosettings will be included. Furthermore, conceptual differences between the short QT syndrome andIKractivation will be accounted for.


  • Pharmacologically Induced Long QT Type 2 Can Be Rescued by Activation of IKs With Benzodiazepine R-L3 in Isolated Guinea Pig Cardiomyocytes

    by Jakob Dahl Msc Nissen, Jonas Goldin Msc Diness, Thomas Goldin Diness, Rie Schultz Hansen, Morten Grunnet, Thomas Jespersen

    The ionic current responsible for terminating the action potential (AP), and thereby in part determining the AP duration (APD), is the potassium current (IK), consisting of primarily two components: a rapidly (IKr) and a slowly (IKs) activating delayed rectifier potassium current. The aim of this study was to evaluate potential antiarrhythmic effects of compound induced IKs activation using the benzodiazepine L-364,373 (R-L3). Ventricular myocytes from guinea pigs were isolated and whole-cell current clamping was performed at 35°C. It was found that 1 μM R-L3 significantly reduced the APD90 at pacing frequencies of 1, 2, and 4 Hz when compared to control (40 ± 6%, 22 ± 2%, and 32 ± 2%, respectively). The reduction of APD90 was accompanied by a reduced triangulation (given as APD30-90) when compared to control at all pacing frequencies (62 ± 7 ms vs. 41 ± 3 ms, 55 ± 5 ms vs. 35 ± 6 ms, and 45 ± 4 ms vs. 32 ± 2 ms, at 1 Hz, 2 Hz, and 4 Hz, respectively). The abbreviated APDs also resulted in a reduction in the relative refractory period, and no direct protection against pacing induced early after-depolarizations (EAD) could be observed. However, an increase in repolarizing capacity was seen with 1 μM R-L3, as more complete repolarization of the AP was achieved before EADs could be elicited. Finally, a functional demonstration of the repolarization reserve revealed that increased IKs can counteract a pharmacologically reduced IKr. In conclusion, pharmacological activation of IKs possesses both pro- and antiarrhythmic characters. The most prominent antiarrhythmic propensity is the ability for IKs activation to rescue a cellular model of long QT type 2.


  • Biophysical Characterization of the Short QT Mutation hERG-N588K Reveals a Mixed Gain-and Loss-of-Function

    by Morten Grunnet, Thomas G. Diness, Rie Schultz Hansen, Søren-Peter Olesen

    The short QT syndrome is a newly discovered pro-arrhythmic condition, which may cause ventricular fibrillation and sudden death. Short QT can originate from the apparent gain-of-function mutation N588K in the hERG potassium channel that conducts repolarising I(Kr) current. The present study describes a profound biophysical characterization of HERG-N588K revealing both loss-of-function and gain-of-function properties of the mutant. Experiments were conducted after heterologous expression in both Xenopus laevis oocytes and mammalian cells and at both room temperature and at 37 degrees C. Also the impact of the beta-subunits KCNE2 was investigated. The most prominent loss-of-function property of HERG-N588K was reduced tail currents but also the activation properties was compromised. Based on these biophysical results we suggest that the general view of HERG-N588K being a gain-of-function is modified to a mixed gain- and loss-of-function mutation. This might also have impact on the pathological picture of the HERG-N588K channels ability to trigger arrhythmic events.


  • hERG1 channel activators: A new anti-arrhythmic principle

    by Morten Grunnet, Rie Schultz Hansen, Søren-Peter Olesen


  • Characterization of hERG1a and hERG1b potassium channels—a possible role for hERG1b in the I Kr current

    by Anders Peter Larsen, Søren-Peter Olesen, Morten Grunnet, Thomas Jespersen

    I Kr is the fast component of the delayed rectifier potassium currents responsible for the repolarization of the cardiac muscle. The molecular correlate underlying the I Kr current has been identified as the hERG1 channel. Recently, two splice variants of the hERG1 α-subunit, hERG1a and hERG1b, have been shown to be co-expressed in human cardiomyocytes. In this paper, we present the electrophysiological characterization of hERG1a, hERG1b, and co-expressed hERG1a/b channels in a mammalian expression system using the whole-cell patch clamp technique. We also quantified the messenger RNA (mRNA) levels of hERG1a and hERG1b in human cardiac tissue, and based on the expressed ratios, we evaluated the resulting currents in Xenopus laevis oocytes. Compared to hERG1a channels, activation was faster for both hERG1b and hERG1a/b channels. The deactivation kinetics was greatly accelerated in the presence of hERG1b, whereas no difference in the time constant of inactivation was observed. The voltage-dependent recovery from inactivation was also similar. However, the time constant of recovery from inactivation was significantly faster for hERG1b channels compared to hERG1a and hERG1a/b. Quantification of hERG1a and hERG1b mRNA in the human heart showed that hERG1b mRNA constitutes, on average, 19% in the right atrium and 12% in the left ventricle of the total hERG1 mRNA. Expression of the observed ratios of hERG1a to hERG1b in X. laevis oocytes showed that these ratios are indeed sufficient to change the deactivation phenotype markedly. The present work suggests that hERG1b is likely to play a role in the formation of the native I Kr current.


  • The Small Molecule NS11021 Is a Potent and Specific Activator of Ca2+-Activated Big-Conductance K+ Channels

    by Bo Hjorth Bentzen, Antonio Nardi, Kirstine Calloe, Lars Siim Madsen, Søren-Peter Olesen, Morten Grunnet

    Large-conductance Ca2+- and voltage-activated K+ channels (Kca1.1/BK/MaxiK) are widely expressed ion channels. They provide a Ca2+-dependent feedback mechanism for the regulation of various body functions such as blood flow, neurotransmitter release, uresis, and immunity. In addition, a mitochondrial K+ channel with KCa1.1-resembling properties has been found in the heart, where it may be involved in regulation of energy consumption. In the present study, the effect of a novel NeuroSearch compound, 1-(3,5-bis-trifluoromethyl-phenyl)-3-[4-bromo-2-(1H-tetrazol-5-yl)-phenyl]-thiourea (NS11021), was investigated on cloned KCa1.1 expressed in Xenopus laevis oocytes and mammalian cells using electrophysiological methods. NS11021 at concentrations above 0.3 μM activated KCa1.1 in a concentration-dependent manner by parallel-shifting the channel activation curves to more negative potentials. Single-channel analysis revealed that NS11021 increased the open probability of the channel by altering gating kinetics without affecting the single-channel conductance. NS11021 (10 μM) influenced neither a number of cloned Kv channels nor endogenous Na+ and Ca2+ channels (L- and T-type) in guinea pig cardiac myocytes. In conclusion, NS11021 is a novel KCa1.1 channel activator with better specificity and a 10 times higher potency compared with the most broadly applied KCa1.1 opener, NS1619. Thus, NS11021 might be a valuable tool compound when addressing the physiological and pathophysiological roles of KCa1.1 channels.


  • Activation of ERG2 potassium channels by the diphenylurea NS1643

    by Pernille Elmedyb, Søren-Peter Olesen, Morten Grunnet